Aurisco Pharmaceutical Co Ltd (605116) — Cash Flow Reinvestment Rate
Aurisco Pharmaceutical Co Ltd (605116) has a Cash Flow Reinvestment Rate of 3.81x as of December 2024, reinvesting CN¥1.27 Billion (capex CN¥540.28 Million plus investments CN¥-726.77 Million) from operating cash flow of CN¥332.41 Million. Check how high is Aurisco Pharmaceutical Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Aurisco Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2017–2024)
Historical reinvestment intensity for Aurisco Pharmaceutical Co Ltd across 8 annual periods. Explore 605116 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Aurisco Pharmaceutical Co Ltd (2017–2024)
Year-by-year capital reinvestment analysis for Aurisco Pharmaceutical Co Ltd. For live market cap and broader valuation context, see Aurisco Pharmaceutical Co Ltd (605116) market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 3.81x | CN¥1.27 Billion | CN¥332.41 Million | CN¥540.28 Million | ▲ +119.1% |
| 2023 | 1.74x | CN¥670.75 Million | CN¥385.61 Million | CN¥305.48 Million | ▼ -38.8% |
| 2022 | 2.84x | CN¥473.01 Million | CN¥166.41 Million | CN¥216.23 Million | ▲ +11.7% |
| 2021 | 2.54x | CN¥512.96 Million | CN¥201.57 Million | CN¥250.61 Million | ▲ +72.8% |
| 2020 | 1.47x | CN¥315.81 Million | CN¥214.48 Million | CN¥158.80 Million | ▲ +71.4% |
| 2019 | 0.86x | CN¥154.57 Million | CN¥179.90 Million | CN¥72.47 Million | ▲ +0.2% |
| 2018 | 0.86x | CN¥94.14 Million | CN¥109.77 Million | CN¥94.14 Million | ▼ -5.1% |
| 2017 | 0.90x | CN¥106.60 Million | CN¥117.91 Million | CN¥106.60 Million | — |